Suggestions
Stefan Longolius
Vice President Early Pipeline & Commercialization Oncology at Bayer Pharmaceuticals
Stefan Longolius is a distinguished leader in the realm of global marketing and development, specializing in the fields of specialty pharmaceuticals with significant expertise in Hemophilia, Multiple Sclerosis, and Inflammatory Bowel Diseases (IBD). With an impressive career spanning over 18 years, Stefan has built a formidable reputation for transforming strategic visions into successful market executions and cultivating cross-functional and cross-regional collaborations. His leadership style is characterized by a commitment to accelerating growth and maximizing the potential of novel therapies, making him a vital asset in the highly competitive pharmaceutical industry.
Stefan's academic background lays a strong foundation for his professional accomplishments. He pursued a PhD in Business Administration at Freie Universität Berlin, where he honed his analytical and strategic thinking skills. Coupled with a Diplom-Kaufmann in Business Administration and Management, his education provides him with a robust understanding of business dynamics, allowing him to synthesize market needs with scientific advancements efficiently. This dual perspective has greatly influenced his approach to positioning specialty pharmaceuticals within the healthcare landscape.
Throughout his career, Stefan has held several key leadership roles that demonstrate his ability to steer complex initiatives. As the Vice President of Strategy & Portfolio Management at Bayer HealthCare, he played a pivotal role in orchestrating strategic initiatives that drive product development and market entry for groundbreaking therapies. His previous position as Vice President of Early Pipeline & Commercialization Oncology further solidified his capabilities in navigating the intricate process of bringing innovative treatments to market, ensuring they meet both regulatory standards and patient needs.
At Bayer HealthCare, Stefan has previously served as the Global Project Leader and Head of the Global Brand Team for Multiple Sclerosis and Crohn’s disease. Here, he adeptly managed integrated brand strategies, underscoring his expertise in brand management and his ability to lead cross-functional teams toward shared objectives. His tenure at Schering AG, now a part of Bayer, provided him with invaluable insights into the operational aspects of pharmaceuticals, where he progressed from Project Manager to Executive Director of Clinical Operations. This breadth of experience not only enhances his leadership skill set but also enriches his understanding of the interdisciplinary nature of pharmaceutical development.
